IL182580A0 - Polymorphic forms of 6-[2- - Google Patents

Polymorphic forms of 6-[2-

Info

Publication number
IL182580A0
IL182580A0 IL182580A IL18258007A IL182580A0 IL 182580 A0 IL182580 A0 IL 182580A0 IL 182580 A IL182580 A IL 182580A IL 18258007 A IL18258007 A IL 18258007A IL 182580 A0 IL182580 A0 IL 182580A0
Authority
IL
Israel
Prior art keywords
polymorphic forms
polymorphic
forms
Prior art date
Application number
IL182580A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL182580A0 publication Critical patent/IL182580A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL182580A 2004-11-02 2007-04-16 Polymorphic forms of 6-[2- IL182580A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62466504P 2004-11-02 2004-11-02
PCT/IB2005/003312 WO2006048751A1 (en) 2004-11-02 2005-10-21 Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole

Publications (1)

Publication Number Publication Date
IL182580A0 true IL182580A0 (en) 2007-07-24

Family

ID=35538878

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182580A IL182580A0 (en) 2004-11-02 2007-04-16 Polymorphic forms of 6-[2-

Country Status (14)

Country Link
US (1) US20060094763A1 (enExample)
EP (1) EP1819696A1 (enExample)
JP (1) JP2008518904A (enExample)
KR (1) KR20070060145A (enExample)
AR (1) AR051945A1 (enExample)
AU (1) AU2005300317A1 (enExample)
BR (1) BRPI0517924A (enExample)
CA (1) CA2586177A1 (enExample)
IL (1) IL182580A0 (enExample)
MX (1) MX2007005273A (enExample)
RU (1) RU2007116150A (enExample)
TW (1) TW200630356A (enExample)
WO (1) WO2006048751A1 (enExample)
ZA (1) ZA200702976B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608952A1 (en) * 2005-05-19 2006-11-23 Dwayne Thomas Friesen Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EP4249063A3 (en) * 2007-04-05 2024-03-13 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
TW201328725A (zh) 2011-09-30 2013-07-16 Pfizer Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物
CA2855211A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN104140414B (zh) * 2013-05-07 2018-12-11 江苏豪森药业集团有限公司 阿昔替尼晶型的制备方法
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
SI3102605T1 (sl) 2014-02-04 2019-04-30 Pfizer Inc. Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
WO2016178150A1 (en) * 2015-05-05 2016-11-10 Shilpa Medicare Limited Novel polymorphs of axitinib
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
WO2018065938A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
WO2020003196A1 (en) * 2018-06-28 2020-01-02 Alembic Pharmaceuticals Limited Pharmaceutical composition of axitinib
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2020212253A1 (en) 2019-04-18 2020-10-22 Synthon B.V. Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt
WO2020225413A1 (en) 2019-05-09 2020-11-12 Synthon B.V. Pharmaceutical composition comprising axitinib
PT3884929T (pt) 2020-03-25 2023-08-09 Ocular Therapeutix Inc Implante ocular contendo um inibidor da tirosina cinase
CN113943271B (zh) * 2020-07-15 2023-11-14 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
CN112174933A (zh) * 2020-08-07 2021-01-05 天津理工大学 一种阿西替尼富马酸盐的新晶型及其制备方法
CN114685436B (zh) * 2020-12-25 2022-12-02 鲁南制药集团股份有限公司 阿昔替尼糖精共晶水合物
CN114685437B (zh) * 2020-12-25 2022-12-09 鲁南制药集团股份有限公司 阿昔替尼与糖精共晶
CN114685431B (zh) * 2020-12-26 2022-11-29 鲁南制药集团股份有限公司 一种阿昔替尼柠檬酸盐晶型
CN114685433B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 一种阿昔替尼香草酸共晶盐及其制备
CN114685435B (zh) * 2020-12-28 2023-01-31 鲁南制药集团股份有限公司 阿昔替尼马来酸盐晶型及其制备
CN114685432B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 阿昔替尼盐晶型及其制备方法
CN114685438B (zh) * 2020-12-28 2023-06-13 鲁南制药集团股份有限公司 一种阿昔替尼苹果酸新盐
AU2023227442A1 (en) 2022-03-03 2024-09-12 Pfizer Inc. Multispecific antibodies and uses thereof
EP4282415A1 (en) 2022-05-26 2023-11-29 Genepharm S.A. A stable tablet composition of axitinib
AU2024251447A1 (en) 2023-04-11 2025-08-21 Ocular Therapeutix, Inc. Ocular implant comprising axitinib polymorph iv
KR20250108329A (ko) 2024-01-08 2025-07-15 (주)유케이케미팜 엑시티닙의 제조방법
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors
KR20250150872A (ko) * 2024-04-12 2025-10-21 주식회사 스카이테라퓨틱스 액시티닙의 신규 분자 회합체
KR102838026B1 (ko) * 2024-04-30 2025-07-28 주식회사 스카이테라퓨틱스 액시티닙 신규 분자 회합체를 포함하는 점안 조성물 및 이의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
KR20070060145A (ko) 2007-06-12
CA2586177A1 (en) 2006-05-11
AR051945A1 (es) 2007-02-21
TW200630356A (en) 2006-09-01
EP1819696A1 (en) 2007-08-22
JP2008518904A (ja) 2008-06-05
MX2007005273A (es) 2007-07-19
RU2007116150A (ru) 2008-11-10
ZA200702976B (en) 2008-08-27
AU2005300317A1 (en) 2006-05-11
US20060094763A1 (en) 2006-05-04
WO2006048751A1 (en) 2006-05-11
BRPI0517924A (pt) 2008-10-21

Similar Documents

Publication Publication Date Title
PL1802579T3 (pl) Pochodne 3-aryloaminopirydynowe
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
EP1735702A4 (en) POLYMORPHIC REGULAR TERMS
IL180742A0 (en) Method of manufacture
GB0823478D0 (en) Method of cementing
IL185757A0 (en) Methods of decreasing calcifcation
IL181185A0 (en) Novel polymorphs of azabicyclohexane
PL1931842T3 (pl) Zespół profili
EP1804582A4 (en) POLYMORPH SHAPES OF TADALAFIL
IL178562A0 (en) Novel androgens
GB0504314D0 (en) Novel polymorph
IL187832A0 (en) Methods and intermediates for the preparation of optionally radio- labeled imatinib
AU158365S (en) Set of fins for surfcraft
IL176953A0 (en) Polymorphic forms of nateglinide
IL186301A0 (en) Hydromorphone polymorphs
GB0506942D0 (en) Method of printing
SI1812422T1 (sl) Kristalna oblika irbesartana
GB2428638B (en) Method of estimating alignment
IL178683A0 (en) Methods of diminishing co-abuse potenitial
GB0415170D0 (en) Method of determination
GB0419826D0 (en) Method of determination
GB0412138D0 (en) Definition of zeroclick
GB0423353D0 (en) Methods of printing
GB0421068D0 (en) Methods of printing
ZA200508325B (en) Manufacture of kerbstones